• Placement to raise $2.5m from high-net-worth investors at $0.004 per share
• Proceeds to support regulatory and manufacturing milestones for BZDS1901 CAR-T therapy
• BZDS1901 shows promising clinical results including complete tumour clearance in mesothelioma patients

AdAlta Limited (ASX:1AD) has received binding commitments to raise A$2.5 million in a private placement to sophisticated investors. The proceeds will further strengthen AdAlta's ability to advance development of BZDS1901, its next generation CAR-T cell therapy for advanced mesothelioma, and execute its 'East to West' strategy. The placement will issue approximately 625 million new shares at $0.004 per share, with one free attaching option for every three shares issued, exercisable at $0.01 and expiring in June 2028. The critical next steps enabled by the placement include engaging with regulators, including the US FDA, to ensure alignment of expectations ahead of clinical trial approval, and moving manufacturing to Australia, which is a major value driver for future commercial partnerships. AdAlta's 'East to West' platform has become increasingly valuable in the evolving geopolitical biotech R&D climate, with recent US regulatory changes limiting the use of clinical data generated in certain countries. The placement was facilitated by Lead Manager 62 Capital Pty Ltd.

AdAlta continues to actively seek additional assets where its 'East to West' globalization platform can add significant value, particularly in light of geopolitical tensions in biotech R&D.